GeneSystem Co

GeneSystem Co Accounts Payable

The Accounts Payable of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 14.97 M KRW. In the previous year, Accounts Payable was 3.13 M KRW — a change of 378.63% (higher).

Accounts Payable

14.97 MKRW

YoY

378.63%

Last updated:

Accounts Payable of GeneSystem Co is 2025 14.97 M KRW. Accounts Payable of GeneSystem Co was 2024 3.13 M KRW. It decreases by 378.63% higher compared to the previous year.

The GeneSystem Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
58.87 M KRW
Jan 1, 2020
222.12 M KRW
Jan 1, 2021
259.43 M KRW
Jan 1, 2023
8.26 M KRW
Jan 1, 2024
3.13 M KRW
Jan 1, 2025
14.97 M KRW
The GeneSystem Co Accounts Payable history
YEARAccounts PayableYoY
14.97 MKRW+378.63%
3.13 MKRW-62.13%
8.26 MKRW-96.82%
259.43 MKRW+16.80%
222.12 MKRW+277.33%
58.87 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Accounts Payable of GeneSystem Co is 14.97 M KRW in 2025.

Accounts Payable of GeneSystem Co changed from 3.13 M KRW to 14.97 M KRW, representing a 378.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneSystem Co

All Key Metrics — GeneSystem Co